Skip to main content Accessibility help

Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials

  • W. Zheng (a1), X-H. Li (a2) (a3), X-H. Yang (a1), D-B. Cai (a4), G. S. Ungvari (a5) (a6), C. H. Ng (a7), S-B. Wang (a8), Y-Y. Wang (a8), Y-P. Ning (a1) and Y-T. Xiang (a8)...



Dysfunction of N-methyl-D-aspartate receptor (NMDAR) is involved in the pathophysiology of schizophrenia. A meta-analysis of randomized controlled trials (RCTs) was conducted to examine the efficacy and safety of memantine, a non-competitive NMDAR antagonist, in the treatment of schizophrenia.


Standardized/weighted mean differences (SMDs/WMDs), risk ratio (RR), and their 95% confidence intervals (CIs) were calculated and analyzed.


Included in the meta-analysis were eight RCTs (n = 452) of 11.5 ± 2.6 weeks duration, with 229 patients on memantine (20 mg/day) and 223 patients on placebo. Adjunctive memantine outperformed placebo in the measures of Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale negative symptoms [SMD: −0.63 (95% CI −1.10 to −0.16), p = 0.009, I 2 = 77%], but not in the total, positive and general symptoms [SMD: −0.46 to −0.08 (95% CI −0.93 to 0.22), p = 0.06–0.60, I 2 = 0–74%] or the Clinical Global Impression Severity Scale [WMD: 0.04 (95% CI −0.24 to 0.32), p = 0.78]. The negative symptoms remained significant after excluding one outlying RCT [SMD: −0.41 (95% CI −0.72 to −0.11), p = 0.008, I 2 = 47%]. Compared with the placebo group, adjunctive memantine was associated with significant improvement in neurocognitive function using the Mini-Mental State Examination (MMSE) [WMD: 3.09, (95% CI 1.77–4.42), p < 0.00001, I 2 = 22%]. There was no significant difference in the discontinuation rate [RR: 1.34 (95% CI 0.76–2.37), p = 0.31, I 2 = 0%] and adverse drug reactions between the two groups.


This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia. Higher quality RCTs with larger samples are warranted to confirm these findings.


Corresponding author

*Address for correspondence: Dr Y-T. Xiang, M.D., Ph.D., Faculty of Health Sciences, University of Macau, Avenida da Universidade, 3/F, Building E12, Taipa, Macau SAR, China. (Email: Or Dr Y-P. Ning, M.D., Ph.D., The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China. (Email:


Hide All

These authors contributed equally to this work.



Hide All
Atkins, D, Best, D, Briss, PA, Eccles, M, Falck-Ytter, Y, Flottorp, S, Guyatt, GH, Harbour, RT, Haugh, MC, Henry, D, Hill, S, Jaeschke, R, Leng, G, Liberati, A, Magrini, N, Mason, J, Middleton, P, Mrukowicz, J, O'Connell, D, Oxman, AD, Phillips, B, Schunemann, HJ, Edejer, T, Varonen, H, Vist, GE, Williams, JW Jr., Zaza, S (2004). Grading quality of evidence and strength of recommendations. British Medical Journal 328, 1490.
Balshem, H, Helfand, M, Schunemann, HJ, Oxman, AD, Kunz, R, Brozek, J, Vist, GE, Falck-Ytter, Y, Meerpohl, J, Norris, S, Guyatt, GH (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 64, 401406.
Carroll, BT, Goforth, HW, Thomas, C, Ahuja, N, McDaniel, WW, Kraus, MF, Spiegel, DR, Franco, KN, Pozuelo, L, Munoz, C (2007). Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. Journal of Neuropsychiatry and Clinical Neurosciences 19, 406412.
de Lucena, D, Fernandes, BS, Berk, M, Dodd, S, Medeiros, DW, Pedrini, M, Kunz, M, Gomes, FA, Giglio, LF, Lobato, MI, Belmonte-de-Abreu, PS, Gama, CS (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. Journal of Clinical Psychiatry 70, 14161423.
DerSimonian, R, Laird, N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177188.
Egger, M, Davey Smith, G, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629634.
Field, JR, Walker, AG, Conn, PJ (2011). Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 17, 689698.
Folstein, MF, Folstein, SE, McHugh, PR (1975). ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189198.
Gama, CS, Andreazza, AC, Kunz, M, Berk, M, Belmonte-de-Abreu, PS, Kapczinski, F (2007). Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 420, 4548.
Gama, CS, Antunes, P, Moser, C, Belmonte-de-Abreu, PS (2005). Memantine as an adjunctive therapy for schizophrenia negative symptoms. Revista Brasileira de Psiquiatria 27, 257258.
Gu, J, Wu, Y, Tang, L (2012). A controlled study of clozapine plus memantine in schizophrenia negative symptoms [In Chinese]. Journal of Clinical Psychiatry 22, 261263.
Guy, W (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology (Revised) (ed. Guy, W.), pp. 217221. National Institute of Mental Health: Rockville.
Higgins, J, Higgins, J (2008). Cochrane Handbook for Systematic Reviews of Interventions. J. Wiley & Sons: Chichester, UK.
Jadad, AR, Moore, RA, Carroll, D, Jenkinson, C, Reynolds, DJ, Gavaghan, DJ, McQuay, HJ (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 17, 112.
John, JP, Lukose, A, Manjunath, S (2014). Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. Pharmacopsychiatry 47, 202209.
Kay, SR, Fiszbein, A, Opler, LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.
Kishi, T, Iwata, N (2013). NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. Journal of Psychiatric Research 47, 11431149.
Koch, HJ, Uyanik, G, Fischer-Barnicol, D (2005). Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. Current Drug Targets CNS and Neurological Disorders 4, 499506.
Krivoy, A, Weizman, A, Laor, L, Hellinger, N, Zemishlany, Z, Fischel, T (2008). Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. European Neuropsychopharmacology 18, 117121.
Lee, JG, Lee, SW, Lee, BJ, Park, SW, Kim, GM, Kim, YH (2012). Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investigation 9, 166173.
Lelorier, J, Grégoire, G, Benhaddad, A, Lapierre, J, Derderian, F (1997). Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New England Journal of Medicine 337, 536542.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, RR, Geddes, JR, Kissling, W, Stapf, MP, Lassig, B, Salanti, G, Davis, JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951962.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM (2009 a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 3141.
Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, Asenjo Lobos, C, Schwarz, S, Davis, JM (2009 b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152163.
Lieberman, JA, Papadakis, K, Csernansky, J, Litman, R, Volavka, J, Jia, XD, Gage, A (2009). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34, 13221329.
Lipton, SA (2004). Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Journal of Alzheimers Disease 6, S61S74.
Marder, SR, Fenton, W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research 72, 59.
Matsuda, Y, Kishi, T, Iwata, N (2013). Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. Journal of Psychiatric Research 47, 20182020.
Mazinani, R, Nejati, S, Khodaei, M (2016). Effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized double-blind, placebo-controlled clinical trial. Psychiatry Research 247, 291295.
Moghaddam, B, Javitt, D (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37, 415.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 151, 264269, W64.
Omranifard, V, Rajabi, F, Mohammadian-Sichani, M, Maracy, M (2015). The effect of add-on memantine on global function and quality of life in schizophrenia: a randomized, double-blind, controlled, clinical trial. Advanced Biomedical Research 4, 22779175.
Overall, JE, Gorham, DR (1962). The brief psychiatric rating-scale. Psychological Reports 10, 799812.
Pieta Dias, C, Martins de Lima, MN, Presti-Torres, J, Dornelles, A, Garcia, VA, Siciliani Scalco, F, Rewsaat Guimaraes, M, Constantino, L, Budni, P, Dal-Pizzol, F, Schroder, N (2007). Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 146, 17191725.
Puangthong, U, Hsiung, GYR (2009). Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. Neuropsychiatric Disease and Treatment 5, 553561.
Rezaei, F, Mohammad-Karimi, M, Seddighi, S, Modabbernia, A, Ashrafi, M, Salehi, B, Hammidi, S, Motasami, H, Hajiaghaee, R, Tabrizi, M, Akhondzadeh, S (2013). Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 33, 336342.
Singh, SP, Singh, V (2011). Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25, 859885.
Sterne, JA, Sutton, AJ, Ioannidis, JP, Terrin, N, Jones, DR, Lau, J, Carpenter, J, Rucker, G, Harbord, RM, Schmid, CH, Tetzlaff, J, Deeks, JJ, Peters, J, Macaskill, P, Schwarzer, G, Duval, S, Altman, DG, Moher, D, Higgins, JP (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 343, d4002.
Tsai, G, Coyle, JT (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology 42, 165179.
Tsai, GE, Lin, PY (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design 16, 522537.
Veerman, SR, Schulte, PF, Smith, JD, de Haan, L (2016). Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychological Medicine 46, 19091921.
Wu, EQ, Birnbaum, HG, Shi, L, Ball, DE, Kessler, RC, Moulis, M, Aggarwal, J (2005). The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry 66, 11221129.
Xiang, YQ, Zheng, W, Wang, SB, Yang, XH, Cai, DB, Ng, CH, Ungvari, GS, Kelly, DL, Xu, WY, Xiang, YT (2017). Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. European Neuropsychopharmacology 27, 818.
Zdanys, K, Tampi, RR (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 13621374.
Zheng, W, Li, Q, Lin, JX, Xiang, YQ, Guo, T, Chen, Q, Cai, DB, Xiang, YT (2016 a). Tai Chi for schizophrenia: a systematic review. Shanghai Archives of Psychiatry 28, 185194.
Zheng, W, Wang, SB, Ungvari, GS, Ng, CH, Yang, XH, Gu, YH, Li, M, Xiang, YQ, Xiang, YT (2017). Amantadine for antipsychotic-related weight Gain: meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychopharmacology 37, 341346.
Zheng, W, Xiang, YT, Xiang, YQ, Li, XB, Ungvari, GS, Chiu, HF, Correll, CU (2016 b). Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatrica Scandinavica 134, 385398.
Zheng, W, Zheng, YJ, Li, XB, Tang, YL, Wang, CY, Xiang, YQ, de Leon, J (2016 c). Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. Journal of Clinical Psychopharmacology 36, 628636.


Type Description Title
Supplementary materials

Zheng supplementary material
Table S1 and Figures S1-S6

 Word (130 KB)
130 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed